Lakefront Biotherapeutics NV current report, Q1 FY2019

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV, a foreign private issuer headquartered in Mechelen, Belgium. The filing date is March 20, 2019, covering the month of March 2019. The registrant files annual reports on Form 20-F. Note: The request metadata references "Lakefront Biotherapeutics NV," but the filing text explicitly identifies the registrant as Galapagos NV.

Financial Metrics

The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely to incorporate a press release by reference and does not contain a financial statement or earnings report.

Material Changes

No material financial changes versus prior periods are detailed in this filing. The document references a press release dated March 20, 2019 (Exhibit 99.1), but the content of that press release is not included in the provided text.

Guidance, Outlook, and Risks

The filing does not contain management commentary, guidance, outlook, or specific risk factors. It states that the information in the attached press release is incorporated by reference into the Company's Registration Statements on Forms F-3 and S-8.

Key Facts for Investor Verification

  • Verify the content of the attached Exhibit 99.1 (Press Release dated March 20, 2019) to understand the material event triggering this filing.
  • Confirm the registrant identity is Galapagos NV, not Lakefront Biotherapeutics NV.
  • Review the referenced Registration Statements (Forms F-3 and S-8) for updated disclosures related to the press release.
  • Note that no financial metrics are disclosed in this specific Form 6-K text.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.